Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Transcription profiling of mouse primary macrophages treated with the chemotherapeutic agent, 5,6-dimethylxanthenone-4-acetic acid,


ABSTRACT: Vascular disrupting agents (VDA) represent a novel approach to the treatment of cancer, resulting in collapse of tumor vasculature and tumor death. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a VDA currently in advanced Phase II clinical trials, yet its precise mechanism of action is unknown despite extensive preclinical and clinical investigations. The data presented herein demonstrate that DMXAA is a novel and specific activator of the TBK1-IRF-3 signaling pathway. DMXAA treatment of primary murine macrophages resulted in robust IRF-3 activation, a ~750-fold increase in IFN-beta mRNA and, in contrast to the potent Toll-like receptor 4 (TLR4) agonist, lipopolysaccharide (LPS), signaling was independent of mitogen-activated protein kinase (MAPK) activation and elicited minimal NF-kappaB-dependent gene expression. DMXAA-induced signaling was critically dependent on the IRF-3 kinase, TBK1, and IRF-3, but MyD88-, TRIF-, IPS-1/MAVS-, and IKKbeta-independent, thus excluding all known TLRs and cytosolic helicase receptors. DMXAA pretreatment of murine macrophages induced a state of tolerance to LPS and vice versa. In contrast to LPS stimulation, DMXAA-induced IRF-3 dimerization and IFN-beta expression were inhibited by salicylic acid (SA). These findings detail a novel pathway for TBK-1-mediated IRF-3 activation and provide new insights into the mechanism of this new class of chemotherapeutic drugs. Experiment Overall Design: Microarray analysis was carried out using Affymetrix® mouse array 430A_2 exposed to total RNA prepared from C57BL/6J or IFN-beta-/- macrophages that had been treated with medium alone or DMXAA for 3 h. Fold-induction was calculated using Affymetrix® GeneChip® Operating Software. A >3-fold increase or decrease between inducible and basal mRNA levels was set as the criteria for inclusion of a gene as modulated.

ORGANISM(S): Mus musculus

SUBMITTER: Stefaine Vogel 

PROVIDER: E-GEOD-7194 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.

Roberts Zachary J ZJ   Goutagny Nadege N   Perera Pin-Yu PY   Kato Hiroki H   Kumar Himanshu H   Kawai Taro T   Akira Shizuo S   Savan Ram R   van Echo David D   Fitzgerald Katherine A KA   Young Howard A HA   Ching Lai-Ming LM   Vogel Stefanie N SN  

The Journal of experimental medicine 20070611 7


Vascular disrupting agents (VDAs) represent a novel approach to the treatment of cancer, resulting in the collapse of tumor vasculature and tumor death. 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a VDA currently in advanced phase II clinical trials, yet its precise mechanism of action is unknown despite extensive preclinical and clinical investigations. Our data demonstrate that DMXAA is a novel and specific activator of the TANK-binding kinase 1 (TBK1)-interferon (IFN) regulatory factor 3  ...[more]

Similar Datasets

2007-03-08 | GSE7194 | GEO
2009-08-21 | E-GEOD-17421 | biostudies-arrayexpress
2016-07-05 | E-GEOD-68140 | biostudies-arrayexpress
2011-09-29 | E-GEOD-32446 | biostudies-arrayexpress
2010-09-24 | E-GEOD-24292 | biostudies-arrayexpress
2012-09-29 | E-GEOD-35436 | biostudies-arrayexpress
2012-03-28 | E-GEOD-19490 | biostudies-arrayexpress
2013-08-15 | E-GEOD-49871 | biostudies-arrayexpress
2012-03-28 | E-GEOD-19492 | biostudies-arrayexpress
2010-12-31 | E-GEOD-19926 | biostudies-arrayexpress